Current treatment options for vulvovaginal atrophy

Expert Review of Obstetrics and Gynecology

Volumn 6, Issue 2, 2011, Pages 141-151

  Burich, Rebekah ^a   Degregorio, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atrophic vaginitis; dyspareunia; vulvovaginal atrophy

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ARZOXIFENE; BAZEDOXIFENE; BIOIDENTICAL HORMONE; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; ESTROGEN; GENISTEIN; HERBACEOUS AGENT; HORMONE; HYALURONIC ACID; ISOFLAVONE DERIVATIVE; KAMPO; LASOFOXIFENE; LUBRICATING AGENT; OSPEMIFENE; POLYCARBOPHIL; PRASTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; VITAMIN D;

ACNE; ANORGASMIA; BLOATING; BREAST BIOPSY; BREAST CANCER; BREAST TENDERNESS; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPAREUNIA; DYSURIA; FEMALE SEXUAL DYSFUNCTION; FLUID RETENTION; GALLBLADDER DISEASE; GINSENG; GYNECOLOGIC DISEASE; HAIR GROWTH; HERBAL MEDICINE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERICUM PERFORATUM; HYPERPLASIA; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NAUSEA; NONHUMAN; ORGASM DISORDER; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SEXUAL AROUSAL DISORDER; SIDE EFFECT; SYMPTOM; THROMBOEMBOLISM; URINARY TRACT INFECTION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS; VAGINAL PRURITUS; VENOUS THROMBOEMBOLISM; VOICE CHANGE; WEIGHT GAIN;

EID: 79952959860     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.11.3     Document Type: Review

References (175)

1. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 12(4), 279-285 (2009).
2. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin. Proc. 85(1), 87-94 (2010).
3. Lewis V. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr. Med. Res. Opin. 25(11), 2689-2698 (2009).
4. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 49(4), 292-303 (2004). (Pubitemid 39505183)
5. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15(4 Pt 1), 661-666 (2008).
6. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Int. J. Gynaecol. Obstet. 88(2), 222-228 (2005).
7. Hill K. The demography of menopause. Maturitas 23(2), 113-127 (1996). (Pubitemid 26160441)
8. Rutanen EM, Heikkinen J, Halonen K et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 10(5), 433-439 (2003).
9. Meisels A. The maturation value. Acta Cytol. 11(4), 249 (1967).
10. Hess R, Austin RM, Dillon S, Chang CC, Ness RB. Vaginal maturation index self-sample collection in mid-life women: Acceptability and correlation with physician-collected samples. Menopause 15(4 Pt 1), 726-729 (2008).
11. Greene JG. Constructing a standard climacteric scale. Maturitas 29(1), 25-31 (1998). (Pubitemid 28247565)
12. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 50(3), 209-221 (2005). (Pubitemid 40269904)
13. Hilditch JR, Lewis J, Peter A et al. A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas 24(3), 161-175 (1996).
14. Blatt MH, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome; failure of effective control as measured by menopausal index. AMA Arch. Intern. Med. 91(6), 792-799 (1953).
15. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 13(2), 132-140 (2010).
16. McGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J. Sex Marital Ther. 26(1), 25-40 (2000). (Pubitemid 30046590)
17. van Die MD, Teede HJ, Bone KM, Reece JE, Burger HG. Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. Menopause 16(4), 792-796 (2009).
18. Indhavivadhana S, Leerasiri P, Rattanachaiyanont M et al. Vaginal atrophy and sexual dysfunction in current users of systemic postmenopausal hormone therapy. J. Med. Assoc. Thai. 93(6), 667-675 (2010).
19. Mehta A, Bachmann G. Vulvovaginal complaints. Clin. Obstet. Gynecol. 51(3), 549-555 (2008).
20. Barlow DH, Samsioe G, van Geelen JM. A study of European womens' experience of the problems of urogenital ageing and its management. Maturitas 27(3), 239-247 (1997). (Pubitemid 27356256)
21. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet. Gynecol. 96(3), 351-358 (2000).
22. Le Donne M, Caruso C, Mancuso A et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-010-1545-7 (2010) (Epub ahead of print).
23. Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: A prevalence study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(2), 107-110 (2001). (Pubitemid 32451986)
24. Collaborative Group on Hormonal Factors in Breast Cancer Breast. Cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084), 1047-1059 (1997).
25. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet. Gynecol. 85(2), 304-313 (1995).
26. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J. Sex. Med. 2(Suppl. 3), 154-165 (2005). (Pubitemid 41727408)
27. Ekin M, Yasar L, Savan K et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch. Gynecol. Obstet. DOI: 10.1007/ s00404-010-1382-8 (2010) (Epub ahead of print).
28. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr. Oncol. 14(Suppl. 1), S20-S40 (2007).
29. Day R, Ganz PA, Costantino JP et al. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol. 17(9), 2659-2669 (1999). (Pubitemid 29415221)
30. Kwan KW, Chlebowski RT. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin. Breast Cancer 9(4), 219-224 (2009).
31. Menezes M, Pereira M, Hextall A. Predictors of female urinary incontinence at midlife and beyond. Maturitas 65(2), 167-171 (2010).
32. Barlow DH, Cardozo LD, Francis RM et al. Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol. 104(1), 87-91 (1997). (Pubitemid 27019901)
33. Delmanto A, Nahas-Neto J, Nahas EA et al. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 139(2), 187-192 (2008).
34. Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve. Clin. J. Med. 75(Suppl. 4), S17-S24 (2008).
35. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J. Natl Cancer Inst. 87(18), 1372-1382 (1995).
36. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J. Clin. Oncol. 16(2), 501-514 (1998). (Pubitemid 28135592)
37. Lester JL, Bernhard LA. Urogenital atrophy in breast cancer survivors. Oncol. Nurs. Forum 36(6), 693-698 (2009).
38. Mortimer JE, Boucher L, Baty J et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J. Clin. Oncol. 17(5), 1488-1492 (1999). (Pubitemid 29220856)
39. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38(5), 281-285 (1981). (Pubitemid 12197189)
40. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. Br. Med. J. 1(6072), 1351-1352 (1977). (Pubitemid 8101738)
41. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstet. Gynecol. 93(2), 258-264 (1999). (Pubitemid 29068103)
42. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21(4), 602-606 (2003). (Pubitemid 46621892)
43. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26(4), 556-562 (2008). (Pubitemid 351264348)
44. Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr. Opin. Obstet. Gynecol. 22(1), 56-60 (2010).
45. Yildirim B, Kaleli B, Duzcan E, Topuz O. The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas 49(4), 334-337 (2004). (Pubitemid 39505188)
46. Abban G, Yildirim NB, Jetten AM. Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3. Eur. J. Histochem. 52(2), 107-114 (2008).
47. Bodnar LM, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J. Nutr. 139(6), 1157-1161 (2009).
48. Checa MA, Garrido A, Prat M et al. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Maturitas 52(1), 70-77 (2005). (Pubitemid 41242745)
49. Kaufert P, Boggs PP, Ettinger B, Woods NF, Utian WH. Women and menopause: Beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause 5(4), 197-202 (1998).
50. Kupferer EM, Dormire SL, Becker H. Complementary and alternative medicine use for vasomotor symptoms among women who have discontinued hormone therapy. J. Obstet. Gynecol. Neonatal Nurs. 38(1), 50-59 (2009).
51. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause 9(1), 72-78 (2002). (Pubitemid 34106167)
52. Rotem C, Kaplan B. Phyto-female complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. Gynecol. Endocrinol. 23(2), 117-122 (2007). (Pubitemid 46481021)
53. Ushiroyama T, Yoshida S, Tadaki K, Ikeda A, Ueki M. A pilot study of a Kampo formula, EH0202, with intriguing results for menopausal symptoms. J. Altern. Complement. Med. 10(2), 397-399 (2004). (Pubitemid 38525746)
54. Obi N, Chang-Claude J, Berger J et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol. Biomarkers Prev. 18(8), 2207-2213 (2009).
55. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: Analysis and commentary. Nutr. J. 7, 17 (2008).
56. Reiter E, Beck V, Medjakovic S, Mueller M, Jungbauer A. Comparison of hormonal activity of isoflavone-containing supplements used to treat menopausal complaints. Menopause 16(5), 1049-1060 (2009).
57. Low Dog T. Menopause: A review of botanical dietary supplements. Am. J. Med. 118(Suppl. 12B), 98-108 (2005).
58. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms- a systematic review. Mol. Nutr. Food Res. 53(9), 1084-1097 (2009).
59. Geller SE, Shulman LP, van Breemen RB et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: A randomized controlled trial. Menopause 16(6), 1156-1166 (2009).
60. Cline JM, Franke AA, Register TC, Golden DL, Adams MR. Effects of dietary isoflavone aglycones on the reproductive tract of male and female mice. Toxicol. Pathol. 32(1), 91-99 (2004). (Pubitemid 38249996)
61. McClain MR, Wolz E, Davidovich A et al. Acute, subchronic and chronic safety studies with genistein in rats. Food Chem. Toxicol. 44(1), 56-80 (2006). (Pubitemid 41773804)
62. Reed SD, Newton KM, LaCroix AZ et al. Vaginal, endometrial, and reproductive hormone findings: Randomized, placebocontrolled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: The Herbal Alternatives for Menopause (HALT) Study. Menopause 15(1), 51-58 (2008).
63. Shams T, Setia MS, Hemmings R et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: A meta-analysis. Altern. Ther. Health Med. 16(1), 36-44 (2010).
64. Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: Quantitative causality evaluation in nine suspected cases. Menopause 16(5), 956-965 (2009).
65. Teschke R. Black cohosh and suspected hepatotoxicity: Inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 17(2), 426-440 (2010).
66. Newton KM, Reed SD, LaCroix AZ et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. Ann. Intern. Med. 145(12), 869-879 (2006). (Pubitemid 351639962)
67. Lipovac M, Chedraui P, Gruenhut C et al. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas 65(3), 258-261 (2010).
68. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician- Gynecologists. Use of botanicals for management of menopausal symptoms. Obstet. Gynecol. 97(Suppl. 6), 1-11 (2001).
69. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus (Chaste- Tree/Berry) in the treatment of menopauserelated complaints. J. Altern. Complement. Med. 15(8), 853-862 (2009).
70. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: A randomized, controlled trial. Menopause 16(1), 156-163 (2009).
71. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 4(2), 144-150 (2001). (Pubitemid 32578829)
72. Albertazzi P. Non-estrogenic approaches for the treatment of climacteric symptoms. Climacteric 10(Suppl. 2), 115-120 (2007). (Pubitemid 47450833)
73. Dickman JR, Koenig RT, Ji LL. American ginseng supplementation induces an oxidative stress in postmenopausal women. J. Am. Coll. Nutr. 28(2), 219-228 (2009).
74. Israel D, Youngkin EQ. Herbal therapies for perimenopausal and menopausal complaints. Pharmacotherapy 17(5), 970-984 (1997). (Pubitemid 27415100)
75. Chung MH, Suzuki S, Nishihara T, Hattori M. Estrogenic effects of a Kampo formula, Tokishakuyakusan, in parous ovariectomized rats. Biol. Pharm. Bull. 31(6), 1145-1149 (2008). (Pubitemid 351871166)
76. Ushiroyama T, Yoshida S, Tadaki K, Ikeda A, Ueki M. Clinical efficacy of EH0202, a Kampo formula, on the health of middle-aged women. Am. J. Chin. Med. 32(5), 755-770 (2004). (Pubitemid 41435131)
77. Scheid V, Ward T, Cha WS, Watanabe K, Liao X. The treatment of menopausal symptoms by traditional East Asian medicines: Review and perspectives. Maturitas 66(2), 111-130 (2010).
78. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas 66(4), 333-343 (2010).
79. Schonberg MA, Wee CC. Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice. J. Womens Health (Larchmt.) 14(6), 507-514 (2005). (Pubitemid 41479255)
80. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. 92(4 Pt 2), 722-727 (1998). (Pubitemid 28440818)
81. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development. Drugs Aging 24(5), 361-379 (2007). (Pubitemid 46790261)
82. Galhardo CL, Soares JM Jr, Simoes RS et al. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin. Exp. Obstet. Gynecol. 33(2), 85-89 (2006). (Pubitemid 44204687)
83. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual. Life Outcomes 3, 47 (2005).
84. Gelfand MM, Moreau M, Ayotte NJ et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: A placebocontrolled study. Menopause 10(1), 29-36 (2003). (Pubitemid 36706319)
85. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsedprogestin regimen in hormone replacement therapy. Int. J. Fertil. Womens Med. 44(6), 286-296 (1999). (Pubitemid 30043395)
86. Bennink HJ. Reprint of: Are all estrogens the same? Maturitas 61(1-2), 195-201 (2008).
87. Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J. Sex. Med. 5(1), 132-138 (2008).
88. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J. Clin. Endocrinol. Metab. 93(12), 4567-4575 (2008).
89. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7(3), 156-161 (2000). (Pubitemid 30249896)
90. Fournier A. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Menopause Int. 16(1), 23-32 (2010).
91. Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br. J. Obstet. Gynaecol. 104(Suppl. 16), 4-13 (1997). (Pubitemid 27501718)
92. Mattsson LA, Bohnet HG, Gredmark T et al. Continuous, combined hormone replacement: Randomized comparison of transdermal and oral preparations. Obstet. Gynecol. 94(1), 61-65 (1999). (Pubitemid 29284427)
93. Nachtigall LE. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery. Am. J. Obstet. Gynecol. 173(3 Pt 2), 993-997 (1995).
94. Sturdee DW. Current hormone replacement therapy: What are the shortcomings? Advances in delivery. Int. J. Clin. Pract. 53(6), 468-472 (1999). (Pubitemid 29433661)
95. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-todate overview. Climacteric 12(2), 91-105 (2009).
96. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst. Rev. 4, CD001405 (2009).
97. Beral V, Banks E, Reeves G, Wallis M. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet 349(9058), 1103-1104 (1997). (Pubitemid 27158270)
98. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002). (Pubitemid 34761611)
99. Hulley S, Furberg C, Barrett-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288(1), 58-66 (2002). (Pubitemid 34705519)
100. Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348(9033), 977-980 (1996). (Pubitemid 26340751)
101. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348(9033), 981-983 (1996). (Pubitemid 26340752)
102. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348(9033), 983-987 (1996). (Pubitemid 26340753)
103. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet. Gynecol. 83(1), 5-11 (1994). (Pubitemid 24027372)
104. Chlebowski RT, Anderson, Garnet L et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15), 1684-1692 (2010).
105. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 65(3), 190-197 (2010).
106. Holmberg L, Anderson H. HABITS (Hormonal Replacement Therapy after Breast Cancer- Is It Safe?), a randomised comparison: Trial stopped. Obstet. Gynecol. 363(9407), 453-455 (2004). (Pubitemid 38210063)
107. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet. Gynecol. 115(4), 839-855 (2010).
108. Grady D, Brown JS, Vittinghoff E et al. Postmenopausal hormones and incontinence: The Heart and Estrogen/ Progestin Replacement Study. Obstet. Gynecol. 97(1), 116-120 (2001). (Pubitemid 32057168)
109. Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293(8), 935-948 (2005). (Pubitemid 40271125)
110. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14(3 Pt 1), 355-369; quiz 370-351 (2007).
111. Labrie F, Cusan L, Gomez JL et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16(1), 30-36 (2009).
112. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med. 156(19), 2213-2217 (1996). (Pubitemid 26361914)
113. Krause M, Wheeler TL, Holly ER, Thomas SE. Systemic effects of vaginally administered estrogen therapy. Female Pelvic Med. Reconstruc. Surg. 16, 188-195 (2010).
114. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N. Engl. J. Med. 298(4), 195-197 (1978). (Pubitemid 8272278)
115. Dorr MB, Nelson AL, Mayer PR et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil. Steril. 94(6), 2365-2368 (2010).
116. Notelovitz M. Urogenital aging: Solutions in clinical practice. Int. J. Gynaecol. Obstet. 59(Suppl. 1), S35-S39 (1997).
117. Hurst BS, Jones AI, Elliot M, Marshburn PB, Matthews ML. Absorption of vaginal estrogen cream during sexual intercourse: A prospective, randomized, controlled trial. J. Reprod. Med. 53(1), 29-32 (2008). (Pubitemid 351219776)
118. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. 49(4), 397-409 (1987). (Pubitemid 17138572)
119. Shulman LP. Androgens and menopause. Minerva Ginecol. 61(6), 491-497 (2009).
120. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 11(3), 181-191 (2008).
121. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21(3), 227-236 (1995).
122. Tuiten A, Van Honk J, Koppeschaar H et al. Time course of effects of testosterone administration on sexual arousal in women. Arch. Gen. Psychiatry 57(2), 149-153; discussion 155-156 (2000). (Pubitemid 30075265)
123. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J. Reprod. Med. 43(10), 847-856 (1998). (Pubitemid 28481075)
124. Labrie F, Belanger A, Belanger P et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J. Steroid Biochem. Mol. Biol. 99(4-5), 182-188 (2006). (Pubitemid 43766081)
125. Labrie F, Luu-The V, Belanger A et al. Is dehydroepiandrosterone a hormone? J. Endocrinol. 187(2), 169-196 (2005). (Pubitemid 41685178)
126. Buster JE. Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone precursor replacement therapy (HPRT). Menopause 16(5), 858-859 (2009).
127. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J. Sex. Med. 7(3), 1284-1290 (2010).
128. de Paula FJ, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 56(1), 69-77 (2007). (Pubitemid 44894790)
129. Foster GV, Zacur HA, Rock JA. Hot flashes in postmenopausal women ameliorated by danazol. Fertil. Steril. 43(3), 401-404 (1985). (Pubitemid 15111127)
130. Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet 360(9348), 1851-1861 (2002). (Pubitemid 35449427)
131. Labrie F, Archer D, Bouchard C et al. Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16(5), 907-922 (2009).
132. Labrie F, Archer D, Bouchard C et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5), 923-931 (2009).
133. Johannsson G, Burman P, Wiren L et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgendeficient women: A placebo-controlled trial. J. Clin. Endocrinol. Metab. 87(5), 2046-2052 (2002). (Pubitemid 34525078)
134. Spark RF. Dehydroepiandrosterone: A springboard hormone for female sexuality. Fertil. Steril. 77(Suppl. 4), S19-S25 (2002). (Pubitemid 34465840)
135. Rubino S, Stomati M, Bersi C et al. Neuroendocrine effect of a short-term treatment with DHEA in postmenopausal women. Maturitas 28(3), 251-257 (1998). (Pubitemid 28162438)
136. Stomati M, Monteleone P, Casarosa E et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol. 14(5), 342-363 (2000).
137. Labrie F, Cusan L, Gomez JL et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J. Steroid Biochem. Mol. Biol. 111(3-5), 178-194 (2008).
138. Labrie F, Cusan L, Gomez JL et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J. Steroid Biochem. Mol. Biol. 110(1-2), 1-9 (2008).
139. Labrie F, Archer D, Bouchard C et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 16(5), 897-906 (2009).
140. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: A review based on recent randomised controlled clinical trials. Gynecol. Endocrinol. 26(11), 804-814 (2010).
141. Rymer J, Chapman MG, Fogelman I, Wilson PO. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 18(2), 127-133 (1994). (Pubitemid 24078939)
142. Nappi RE, Ferdeghini F, Sampaolo P et al. Clitoral circulation in postmenopausal women with sexual dysfunction: A pilot randomized study with hormone therapy. Maturitas 55(3), 288-295 (2006). (Pubitemid 44397355)
143. Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 359(7), 697-708 (2008).
144. Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 58(2), 164-173 (2007). (Pubitemid 47503633)
145. Stovall DW. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr. Opin. Investig. Drugs 11(4), 464-471 (2010).
146. Bai WP, Wang SY, Liu JL et al. [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms]. Zhonghua Fu Chan Ke Za Zhi 44(8), 597-600 (2009).
147. de Vries CS, Bromley SE, Thomas H, Farmer RD. Tibolone and endometrial cancer: A cohort and nested case-control study in the UK. Drug Saf. 28(3), 241-249 (2005). (Pubitemid 40364890)
148. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470), 1543-1551 (2005).
149. Sites CK. Bioidentical hormones for menopausal therapy. Womens Health (Lond. Engl.) 4(2), 163-171 (2008). (Pubitemid 351513636)
150. Cirigliano M. Bioidentical hormone therapy: A review of the evidence. J. Womens Health (Larchmt.) 16(5), 600-631 (2007). (Pubitemid 47093906)
151. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet. Gynecol. Surv. 63(3), 163-181 (2008). (Pubitemid 351612435)
152. Nath A, Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric 12(3), 188-205 (2009).
153. Pinkerton JV, Goldstein SR. Endometrial safety: A key hurdle for selective estrogen receptor modulators in development. Menopause 17(3), 642-653 (2010).
154. Wang XN, Simmons HA, Salatto CT, Cosgrove PG, Thompson DD. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor b and androgen receptor in rats. Menopause 13(4), 609-620 (2006). (Pubitemid 44079531)
155. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin. Pharmacother. 10(13), 2209-2220 (2009).
156. Gass M, Bachmann GM, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM), improves dyspareunia in postmenopausal women with vaginal atrophy (VA). Menopause 12, 238 (2005).
157. Gass M, Bachnamm G, Moffett A, Symons J. Clinical signs of vaginal atrophy are improved by the SERM, lasofoxifene. Menopause 11, 670 (2004).
158. Simon GM, Kagan R, Spino C, Nemmeth MA. Lasofoxifene effectively treats dyspareunia in postmenopausal women with vaginal atrophy. Obstet. Gynecol. 105, 102S (2005).
159. Bolognese MA. SERMs and SERMs with estrogen for postmenopausal osteoporosis. Rev. Endocr. Metab. Disord. 11(4), 253-259 (2010).
160. Gennari L. Lasofoxifene (Pfizer). Curr. Opin. Invest. Drugs 6(10), 1067-1078 (2005).
161. Pickar JH, Macneil T, Ohleth K. SERMs: Progress and future perspectives. Maturitas 67(2), 129-138 (2010).
162. Komm BS, Kharode YP, Bodine PV et al. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 146(9), 3999-4008 (2005). (Pubitemid 41175771)
163. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149(12), 6084-6091 (2008).
164. Ronkin S, Northington R, Baracat E et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet. Gynecol. 105(6), 1397-1404 (2005). (Pubitemid 40734275)
165. Pickar JH. The endometrium-from estrogens alone to TSECs. Climacteric 12(6), 463-477 (2009).
166. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/ conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17(2), 281-289 (2010).
167. Vardy MD, Lindsay R, Scotti RJ et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am. J. Obstet. Gynecol. 189(1), 81-88 (2003). (Pubitemid 36886529)
168. Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E. The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil. Steril. 88(2), 530-532 (2007). (Pubitemid 47212133)
169. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2727-2741 (2006).
170. Parsons A, Merritt D, Rosen A et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet. Gynecol. 101(2), 346-352 (2003). (Pubitemid 36170137)
171. Pinkerton JV, Shifren JL, La Valleur J et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 10(1), 45-52 (2003). (Pubitemid 36706321)
172. Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin. Investig. Drugs 18(6), 839-849 (2009).
173. Qu Q, Zheng H, Dahllund J et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 141(2), 809-820 (2000). (Pubitemid 32250507)
174. Gennari L. Ospemifene hormos. Curr. Opin. Investig. Drugs 5(4), 448-455 (2004).
175. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal Phase 3 study. Menopause 17(3), 480-486 (2010).